Fund Utilization - The net proceeds from the rights issue amounting to HKD 507,160,000 have been fully utilized as of December 31, 2023[1]. - Approximately HKD 246,000,000 was allocated for investments in the Chinese healthcare industry[1]. - Around HKD 164,160,000 was used to seek suitable investment opportunities[1]. - HKD 97,000,000 was dedicated to the continued development of the dental business[1]. Dental Business Expenditure - For the fiscal year ending December 31, 2023, HKD 5,050,000 was specifically used for the dental business[2]. - The breakdown of the HKD 5,050,000 includes HKD 3,196,000 for operating costs, HKD 1,604,000 for product R&D, and HKD 250,000 for marketing[2]. Investment Valuation - The fair value of significant investments in Zhuhai Jinyiming Equity Investment Fund Partnership and Haoyikang Health Services (Shenzhen) Partnership is HKD 144,000,000 and HKD 49,100,000 respectively[3]. - These investments represent approximately 23.8% and 8.1% of the total assets as of December 31, 2023[3]. - The previously reported percentages for these investments were corrected from 74.6% and 25.4%[3]. - All other information in the annual report remains unchanged despite these clarifications[3].
佳兆业健康(00876) - 2024 - 年度业绩